Kyowa Hakko Kogyo Co., Ltd.

Kyowa Hakko Kirin Co., Limited

University of Miyazaki

Kyowa Hakko Bio Co., Ltd.

Techno Network Shikoku Co., Ltd.

Tecno Network Shikoku Co., Ltd.

Motoo Yamasaki

Nobuo Hanai

Kazuyasu Nakamura

Kazuhisa Uchida

Emi Hosaka

Toyohide Shinkawa

Yutaka Kanda

Naoko Yamane

Mitsuo Satoh

Kazuya Yamano

Toshiyuki Suzawa

Hideharu Anazawa

Kenji Shibata

Susumu Imabeppu

Akiko Furuya

Kazuo Yamaguchi

Masami Okabe

Makoto Morimoto

Moriyuki Sato

Seiga Itoh

Yoshiharu Yokoo

Hiromasa Miyaji

Tetsuro Kuga

Yoshinori Komatsu

Kenya Shitara

Hajime Yoshida

Keiichi Yano

Takeo Tanaka

Ken Kobayashi

Eiji Tsukuda

Rinpei Niwa

Kazuo Kitamura

Mikiko Sakurada

Kinya Yamashita

Takashi Kuwabara

Tatsuhiro Ogawa

Kumiko Maruyama

Emi Shoji

Tatsuya Murakami

Hiromitsu Saito

Isao Kawamoto

Yuzuru Matsuda

Shigeto Kitamura

Shigeru Chiba

So Ohta

Mayumi Yoshida

Yoshikazu Morishita

Akira Tanaka

Toshihide Ikemura

Yoshimi Honma

Genkichi Ishikawa

Mayumi Mukai

Noboru Konishi

Chieko Bando

Mika Makino

Shiro Akinaga

Yasuhisa Shiraishi

Tatsuya Tamaoki

Satoru Nagamura

Hisao Nemoto

Noriko Sakurai

Takeshi Takahashi

Hiroyuki Yamaguchi

Koji Yamada

Tamio Mizukami

Tetsuji Ohno

Ichiro Miki

Yukimasa Shiotsu

Yasuki Kato

Haruhiko Yokoi

Soichiro Sato

Shiro Soga

Nobuo Kosaka

Hiroko Kusano

Yoko Kato

Satoshi Kobayashi

Masahiro Yamauchi

Tetsuo Yoshida

Maiko Hirota

Naoki Shimada

Keiji Tanaka

Takahiro Moriyama

Osamu Mikuni

Kaoru Miyamoto

Toshiyuki Suzuwa

Masako Hamada

Toshiaki Kamei

Toshiaki Saeki

Masaaki Ando

Noriko Sukurai

Sayaka Nagata

Kazuhisa c/o Head Office Kyowa Kogyo Co Ltd Uchida

Emi c/o Biofrontier Laboratories Kyowa Hakko Kogyo Co Ltd Hosaka

Toyohide c/o Bio Process Research And Development Lab Shinkawa

The invention provides a novel adrenomedullin derivative sustainable for a long period which is capable of substantially suppressing unwanted side effects while maintaining pharmacological effects of adrenomedullin. In an exemplary embodiment, the invention relates to a compound represented by formula (I): A-CH—B (I) [wherein A is a modifying group comprising one or more polyethylene glycol groups, and B is a peptide moiety derived from adrenomedullin or a modified form thereof with adrenomedullin activity, wherein the peptide moiety B is linked to the other moieties through a covalent bond of the nitrogen atom of the N-terminal α-amino group of the peptide moiety B to the carbon atom of the methylene group] or a salt thereof, or a hydrate thereof.

Long-acting adrenomedullin derivative

The invention provides a novel adrenomedullin derivative sustainable for a long period which is capable of substantially suppressing unwanted side effects while maintaining pharmacological effects of adrenomedullin. An aspect of the invention relates to a compound represented by formula (I): [wherein A is an Fc region of an immunoglobulin, B is a peptide moiety derived from adrenomedullin or a modified form thereof with adrenomedullin activity, and L is a linking group comprising a peptide having any given amino acid sequence] or a salt thereof, or a hydrate thereof. Another aspect of the invention relates to a method for producing the compound represented by formula (I), and a medicament comprising the compound as an active ingredient.A-L-B&#x2003;&#x2003;(I).

Long-acting adrenomedullin derivative conjugated with Fc region of immunoglobulin

The invention provides a novel adrenomedullin derivative sustainable for a long period which is capable of substantially suppressing unwanted side effects while maintaining pharmacological effects of adrenomedullin. In an exemplary embodiment, the invention relates to a compound represented by formula (I): A-CH-B (I) [wherein A is a modifying group comprising one or more polyethylene glycol groups, and B is a peptide moiety derived from adrenomedullin or a modified form thereof with adrenomedullin activity, wherein the peptide moiety B is linked to the other moieties through a covalent bond of the nitrogen atom of the N-terminal &#x3b1;-amino group of the peptide moiety B to the carbon atom of the methylene group] or a salt thereof, or a hydrate thereof.

The invention provides a novel adrenomedullin derivative sustainable for a long period which is capable of substantially suppressing unwanted side effects while maintaining pharmacological effects of adrenomedullin. In an exemplary embodiment, the invention relates to a compound represented by formula (I): A-CH&#x2014;B (I) [wherein A is a modifying group comprising one or more polyethylene glycol groups, and B is a peptide moiety derived from adrenomedullin or a modified form thereof with adrenomedullin activity, wherein the peptide moiety B is linked to the other moieties through a covalent bond of the nitrogen atom of the N-terminal &#x3b1;-amino group of the peptide moiety B to the carbon atom of the methylene group] or a salt thereof, or a hydrate thereof.

The present invention relates to an antibody or antibody fragment comprising novel Cys residue, to which a hydrophilic macromolecular group or amphipathic macromolecular group can be bound at a high efficiency. In addition, the present invention relates to a monoclonal antibody modified product or an antibody fragment modified product in which cysteine residue is chemically modified.

Antibody and antibody fragment introduced new modification sites

The present invention relates to a cell for the production of an antibody molecule such as an antibody useful for various diseases having high antibody-dependent cell-mediated cytotoxic activity, a fragment of the antibody and a fusion protein having the Fc region of the antibody or the like, a method for producing an antibody composition using the cell, the antibody composition and use thereof.

Antibody composition-producing cell

The invention relates to a method for controlling the activity of an immunologically functional molecule, such as an antibody, a protein, a peptide or the like, an agent of promoting the activity of an immunologically functional molecule, and an immunologically functional molecule having the promoted activity.

Method of modulating the activity of functional immune molecules

The present invention relates to a cell for the production of an antibody molecule such as an antibody useful for various diseases having high antibody-dependant cell-mediated cytotoxic activity, a fragment of the antibody and a fusion protein having the Fc region of the antibody or the like, a method for producing an antibody composition using the cell, the antibody composition and use thereof.

A recombinant antibody or the antibody fragment thereof which specifically reacts with an extracellular domain of human CCR4; a DNA which encodes the recombinant antibody or the antibody fragment thereof; a method for producing the recombinant antibody or the antibody fragment thereof; a method for immunologically detecting CCR4, a method for immunologically detecting a cell which expressed CCR4 on the cell surface, a method for depleting a cell which expresses CCR4 on the cell surface, and a method for inhibiting production of Th2 cytokine, which comprise using the recombinant antibody according or antibody fragment thereof; a therapeutic or diagnostic agent for Th2-mediated immune diseases; and a therapeutic or diagnostic agent for a blood cancer.

Method for producing recombinant antibody and antibody fragment thereof

The present invention relates to a cell and mammal in which GDP-mannose 4,6-dehydratase is knocked-out. The cell and mammal are useful for the production of an antibody molecule having high antibody-dependent cell-mediated cytotoxic activity, such as an antibody useful for treating various diseases. The cell and mammal are also useful for the production of a fragment of the antibody, and a fusion protein having the Fc region of the antibody.

Cells with altered fucosylation and producing antibodies therefrom

Method for treating the Th2-mediated disease

Growing community of inventors

Machida, Japan

Motoo Yamasaki